

First Investment: 2014
EXIT - NYSE: DNA
The solutions to many of the hardest problems in agriculture, nutrition, pharmaceuticals, energy production, and chemical and material processing lie in synthetic biology. Ginkgo runs biological foundries where automation, machine learning, and analytics work in synchrony to help partners scale up the engineering and manufacture of novel enzymes, proteins, small molecules, and microbial strains.
News & Insights

Thoughts
Explore Companies

Newleos Therapeutics
Transforming the treatment of anxiety and other neuropsychiatric disorders

Grove Biopharma
Putting protein-like drugs inside cells to fight cancer and neurodegeneration

Syntax Bio
Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs